DE2600311A1 - Markierte phospholipoidsphaeren fuer die organdarstellung - Google Patents
Markierte phospholipoidsphaeren fuer die organdarstellungInfo
- Publication number
- DE2600311A1 DE2600311A1 DE19762600311 DE2600311A DE2600311A1 DE 2600311 A1 DE2600311 A1 DE 2600311A1 DE 19762600311 DE19762600311 DE 19762600311 DE 2600311 A DE2600311 A DE 2600311A DE 2600311 A1 DE2600311 A1 DE 2600311A1
- Authority
- DE
- Germany
- Prior art keywords
- phospholipoid
- aggregate
- concentration
- pls
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000056 organ Anatomy 0.000 title claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 75
- 238000012360 testing method Methods 0.000 claims description 69
- 210000004072 lung Anatomy 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 210000004185 liver Anatomy 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 38
- 239000002245 particle Substances 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 230000004807 localization Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 230000004931 aggregating effect Effects 0.000 claims description 16
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 239000001110 calcium chloride Substances 0.000 claims description 13
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 13
- 150000001768 cations Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000084 colloidal system Substances 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 239000004227 calcium gluconate Substances 0.000 claims description 8
- 229960004494 calcium gluconate Drugs 0.000 claims description 8
- 235000013927 calcium gluconate Nutrition 0.000 claims description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 238000001246 colloidal dispersion Methods 0.000 claims 1
- 238000013100 final test Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 229940028435 intralipid Drugs 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- -1 iron (III) ions Chemical class 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229950009740 molybdenum mo-99 Drugs 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000053208 Porcellio laevis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/539,134 US3992513A (en) | 1975-01-07 | 1975-01-07 | Labelled phospholipid material colloidially dispersed and sized to localize at preselected organs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2600311A1 true DE2600311A1 (de) | 1976-07-08 |
Family
ID=24149936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762600311 Pending DE2600311A1 (de) | 1975-01-07 | 1976-01-07 | Markierte phospholipoidsphaeren fuer die organdarstellung |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US3992513A (enExample) |
| CA (1) | CA1100871A (enExample) |
| DE (1) | DE2600311A1 (enExample) |
| FR (1) | FR2297034A1 (enExample) |
| GB (1) | GB1503461A (enExample) |
| NL (1) | NL7600104A (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070493A (en) * | 1977-03-16 | 1978-01-24 | Merck & Co., Inc. | Diagnostic kit |
| US4310506A (en) * | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US4310505A (en) * | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4387087A (en) * | 1980-04-18 | 1983-06-07 | Research Corporation | Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging |
| US4489054A (en) * | 1980-04-18 | 1984-12-18 | Research Corporation | Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging |
| US4406876A (en) * | 1980-10-14 | 1983-09-27 | Research Foundation Of The State Univ. Of New York | Sulfur free small-particle production of technetium sulfur colloid |
| JPS59500431A (ja) * | 1982-03-25 | 1984-03-15 | マリンクロット インコ−ポレ−テッド | 放射性霧状体を供給する装置 |
| US5435989A (en) * | 1982-03-30 | 1995-07-25 | Vestar, Inc. | Method of targeting a specific location in a body |
| US5441745A (en) * | 1982-03-30 | 1995-08-15 | Vestar, Inc. | Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body |
| GB8310038D0 (en) * | 1983-04-13 | 1983-05-18 | Amersham Int Plc | Technetium-99 labelled tin colloid |
| US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| IE58124B1 (en) * | 1984-11-23 | 1993-07-14 | Vestar Inc | The use of micellular particles for making compositions for targeting tumors in humans |
| US4877619A (en) * | 1986-08-25 | 1989-10-31 | Vestar, Inc. | Liposomal vesicles for intraperitoneal administration of therapeutic agents |
| JP2710847B2 (ja) * | 1987-11-04 | 1998-02-10 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | 中性子捕獲療法剤およびその製法 |
| US5328678A (en) * | 1987-11-04 | 1994-07-12 | Vestar, Inc. | Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy |
| US5874059A (en) * | 1992-04-02 | 1999-02-23 | Fundacao E.J. Zerbini | Microemulsions labelled with radioactivity used as means for targeting neoplastic cells |
| BR9201168A (pt) * | 1992-04-02 | 1994-04-12 | Zerbini E J Fundacao | Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas |
| US5851510A (en) * | 1994-05-16 | 1998-12-22 | The Board Of Regents Of The University Of Michigan | Hepatocyte-selective oil-in-water emulsion |
| US5607653A (en) * | 1995-03-17 | 1997-03-04 | Mainstream Engineering Corporation | Process and apparatus for oxidizing and neutralizing caustic waste to liquid fertilizer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663685A (en) * | 1968-04-01 | 1972-05-16 | Minnesota Mining & Mfg | Biodegradable radioactive particles |
| US3597455A (en) * | 1969-05-29 | 1971-08-03 | Squibb & Sons Inc | Process for manufacture of sterile lecithin |
| BE786566A (fr) * | 1971-07-20 | 1973-01-22 | Squibb & Sons Inc | Agregats a base de tc-99m et d'albumine |
| US3863004A (en) * | 1972-03-20 | 1975-01-28 | Mallinckrodt Chemical Works | Denatured macroprotein with divalent tin for tagging with technetium-99m and method of preparation |
-
1975
- 1975-01-07 US US05/539,134 patent/US3992513A/en not_active Expired - Lifetime
- 1975-12-12 CA CA241,628A patent/CA1100871A/en not_active Expired
-
1976
- 1976-01-06 GB GB294/76A patent/GB1503461A/en not_active Expired
- 1976-01-07 NL NL7600104A patent/NL7600104A/xx not_active Application Discontinuation
- 1976-01-07 DE DE19762600311 patent/DE2600311A1/de active Pending
- 1976-01-07 FR FR7600251A patent/FR2297034A1/fr active Granted
- 1976-05-12 US US05/685,587 patent/US4086330A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA1100871A (en) | 1981-05-12 |
| US4086330A (en) | 1978-04-25 |
| NL7600104A (nl) | 1976-07-09 |
| FR2297034B1 (enExample) | 1978-11-03 |
| FR2297034A1 (fr) | 1976-08-06 |
| GB1503461A (en) | 1978-03-08 |
| US3992513A (en) | 1976-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2600311A1 (de) | Markierte phospholipoidsphaeren fuer die organdarstellung | |
| DE2814038C3 (de) | Mit einem Radionuklid für radioaktive Tests markierbares Material | |
| DE2538388A1 (de) | Verfahren zur herstellung eines stabilen, nicht-radioaktiven traegermaterials und seine verwendung zur herstellung von tc-99m-markierten diagnosemitteln | |
| DE2314059A1 (de) | Verbesserte substanz fuer das markieren mit technetium-99m sowie verfahren zu deren herstellung | |
| DE3587541T2 (de) | Stabilisierung von Vesikeln. | |
| DE2235681A1 (de) | Macroaggregate aus albumin, technetium99m und zinn(ii)-ionen, verfahren zu ihrer herstellung und ihre verwendung als radioindikatoren bei der untersuchung von organen | |
| CH641046A5 (de) | Verfahren zur herstellung bestaendiger urokinasemittel. | |
| DE2951783A1 (de) | Mittel zum eichen von geraeten zum messen der haematologischen werte von vollstaendigen blutproben und verfahren zu seiner herstellung | |
| DE3650048T2 (de) | Verfahren und Vorrichtung zur selektiven Bestrahlung biologischer Materialien. | |
| DE2708324A1 (de) | Radioaktiv markiertes scanningmittel | |
| DE2124752A1 (de) | Verfahren zur Herstellung eines diagnostischen Präparats auf Basis von Makroaggregaten von mit 99mTc markiertem Serumeiweiß | |
| DE69914748T2 (de) | Radiojodierte phenole für brachytherapie | |
| DE2234382C3 (de) | Verfahren zur in-vitro-Bestimmung einer physiologisch aktiven Substanz in einer Körperflüssigkeit | |
| EP0509026A1 (de) | Verwendung eines antikoagulant als diagnostikum | |
| DE2710728C2 (de) | Reagens für die radiologische Abtastung von Organen, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE2447556A1 (de) | Radiopharmazeutikum | |
| DE1916704C3 (de) | Freifließendes, pulverförmiges, parenteral anzuwendendes Trägermaterial für radioaktive Substanzen und Verfahren zu dessen Herstellung | |
| DE2419310C3 (de) | Verwendung von Tc-99m-Komplexen | |
| DE2909355A1 (de) | Albumin-mikroaggregate zur radioaktiven darstellung von retikulo-endothelialen systemen | |
| DE3880691T2 (de) | Zusammensetzung und verfahren zur anwendung von in liposomen eingeschlossenen verbindungen in der neutroneneinfangtherapie von tumoren. | |
| DE2025718B2 (de) | Verfahren zum Stabilisieren von lyophilisierten Erythrozyten | |
| DE2239791A1 (de) | Verfahren zur herstellung von mit indium-113m markiertem humantransferrin | |
| DE2621311C3 (de) | Verfahren zum Herstellen von mittels Technetium 99↑m↑ markierten Proteinen | |
| DE3048029A1 (de) | Radioassay-methode fuer warmbluetler zur lokalisierung einer entzuendungsreaktion | |
| CH652308A5 (de) | Radioaktive loesung fuer radiountersuchungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |